Talk:Rabeprazole/GA1

From WikiProjectMed
Jump to navigation Jump to search

GA Review

GA toolbox
Reviewing

Article (edit | visual edit | history) · Article talk (edit | history) · Watch

Reviewer: Tom (LT) (talk · contribs) 10:11, 28 November 2017 (UTC)[reply]


I will take up this review, about one of my favourite drugs. Give me some time to familiarise myself with the page, and I'll respond in 2-3 days. --Tom (LT) (talk) 10:11, 28 November 2017 (UTC)[reply]

Assessment

Rate Attribute Review Comment
1. Well-written:
1a. the prose is clear, concise, and understandable to an appropriately broad audience; spelling and grammar are correct.
1b. it complies with the Manual of Style guidelines for lead sections, layout, words to watch, fiction, and list incorporation.
2. Verifiable with no original research:
2a. it contains a list of all references (sources of information), presented in accordance with the layout style guideline.
2b. reliable sources are cited inline. All content that could reasonably be challenged, except for plot summaries and that which summarizes cited content elsewhere in the article, must be cited no later than the end of the paragraph (or line if the content is not in prose). Will verify no discrepancies found
2c. it contains no original research.
2d. it contains no copyright violations or plagiarism. Nil issues
3. Broad in its coverage:
3a. it addresses the main aspects of the topic. See comments nil issues
3b. it stays focused on the topic without going into unnecessary detail (see summary style).
4. Neutral: it represents viewpoints fairly and without editorial bias, giving due weight to each. See comments
5. Stable: it does not change significantly from day to day because of an ongoing edit war or content dispute.
6. Illustrated, if possible, by media such as images, video, or audio:
6a. media are tagged with their copyright statuses, and valid non-free use rationales are provided for non-free content.
6b. media are relevant to the topic, and have suitable captions.
7. Overall assessment.

Comments

  • @Biochemistry&Love great work on this article, it's really easy to read and I think you've done a great job writing it up. I have a few comments at the moment and will expand a greater list when I have some more time to go through the text and references with a more fine-toothed comb.
    • "History" section is very short. Doesn't actually state who developed it or how
    • "Legal" lists only UK and US which form a small proportion of the world's population. I think it would be more representative to (if possible) add its legal status in the EU, China and India. --Tom (LT) (talk) 06:24, 1 December 2017 (UTC)[reply]
      • Much agreed! Added EU, India, and Japan. I haven't found China yet.―Biochemistry🙴❤ 20:44, 2 December 2017 (UTC)[reply]
    • Still thinking about some of the wording, especially these two sentences "but it is unclear if these effects were due to rabeprazole or extenuating circumstances", and "Theoretical side effects"... wondering if these are straying into WP:PEACOCK territory See below --Tom (LT) (talk) 21:40, 2 December 2017 (UTC)[reply]
    • No image problems
    • Will check copyright Nil issues --Tom (LT) (talk) 21:40, 2 December 2017 (UTC)[reply]
    • Will update review in 1-2 days. --Tom (LT) (talk) 06:24, 1 December 2017 (UTC)[reply]
      • References check is the only thing that is pending. --Tom (LT) (talk) 21:40, 2 December 2017 (UTC)[reply]

Wording

As stated above this article is really easy to read and I think does a great job of communicating its subject matter. Some fairly small changes to increase the readability:--Tom (LT) (talk) 21:39, 2 December 2017 (UTC)[reply]

Lead
  • "Rabeprazole is an antiulcer drug of the proton pump inhibitor class. It is used to suppress gastric acid production for a number of medical uses" -> "Rabeprazole is a proton pump inhibitor used to suppress gastric acid production for a number of medical uses" for accuracy
  • Suggest breakup the lead into 2-3 paragraphs and include information about what its indications are
Medical uses
  • "hypersecretory (too much secretion) " -> "conditions with excess acid secretion"
  • Suggest wikilink the medical conditions to respective articles
  • Reword "In general, the safest possible route is to avoid using rabeprazole while breast feeding" to avoid WP:HOWTO
  • Suggest wikilink "area under the curve"
  • "Renal or hepatic dysfunction" -> Suggest change to "Kidney or liver dysfunction" for ease of understanding
  • "but not to the degree that dangerous accumulation of the drug in the plasma would be expected to occur" -> "but not to a degree of dangerous accumulation"
Adverse effects
  • "However, the most common side effects " -> remove "However"
  • "Rare side effects include rashes, flu-like symptoms, and infections" would be good to know what type of infections
    • Clarified: C dif infx. ―Biochemistry🙴❤ 12:36, 3 December 2017 (UTC)[reply]
      •  Question: source " "ACIPHEX". Eisai Inc. " needs to be fixed up. The source you've provided isn't verifiable... will need some more information --Tom (LT) (talk) 11:30, 7 December 2017 (UTC)[reply]
        • Eep, good point! I've clarified that this is the package insert & added a link.―Biochemistry🙴❤ 05:13, 9 December 2017 (UTC)[reply]
  • "liver injury (hepatotoxicity) have been reported in the literature" -> (a) "liver injury", removing hepatotoxicity; and (b) remove "in the literature"
    • I've clarified that hepatotoxicity is the technical definition. Removed "in the literature." Let me know if this is sufficient. ―Biochemistry🙴❤ 12:31, 3 December 2017 (UTC)[reply]
  • "coma, and death" if these are a result of an already mentioned side-effect, then I suggest reword to "which are potentially fatal" to clarify which side-effects cause this; I am certain death is not an idiopathic side-effect
    • Per the PI, I believe these are listed as idiopathic ADRs. See Postmarketing Experience (sect. 6.2). ―Biochemistry🙴❤ 12:37, 3 December 2017 (UTC)[reply]
      • I see, how interesting and somewhat concerning. --Tom (LT) (talk) 11:30, 7 December 2017 (UTC)[reply]
        • Fairly so--though I think it's debatable if such effects are even due to the drug product. Post-marketing experience often encapsulates more than that which can be directly attributable to the drug; however, there are definitely some easily attributable risks in there (e.g. the inc. C. diff risk has clear biological plausibility). ―Biochemistry🙴❤ 05:17, 9 December 2017 (UTC)[reply]
  • "Rabeprazole is associated with elevated serum gastrin levels, which are thought to be dependent upon the degree of CYP2C19 metabolism the drug undergoes. Notably, rabeprazole is not as significantly metabolized by this enzyme compared to other medications in the same class, like omeprazole.[1]" might belong better in a different section
    • Elevated serum gastrin is an ADR. I've clarified the wording to emphasize the comparison between rabeprazole and omeprazole on this ADR. ―Biochemistry🙴❤ 23:23, 3 December 2017 (UTC)[reply]
  • "but it is unclear if these effects were due to rabeprazole or extenuating circumstances" and "Theoretical side effects": I am somewhat concerened here about WP:PEACOCK / overly promotional language. If this could be reworded that would be great
  • Acid suppressive drugs are associated with a slight increase in the risk of gastric cancer [1]
    • This is related to the hypergastrinemia side effect, mentioned under the ADRs. The meta-analysis you've cited doesn't specifically address rabeprazole, though a couple of the studies analyzed included rabeprazole (only one by name). I'm not sure I feel comfortable declaring that acid suppressants increase gastric cancer based on that study, though I can certainly see the biological plausibility for such a claim. I'm just not sure that the evidence is conclusive yet--for any acid suppressant. How do you feel about the qualifier, "may be associated," instead?―Biochemistry🙴❤ 23:51, 3 December 2017 (UTC)[reply]
      • Happy with this wording. Evidence presented in metaanalysis for PPIs and rabeprazole in particular is not large enough to say definitively, as you state. --Tom (LT) (talk) 11:30, 7 December 2017 (UTC)[reply]
        • Edited! Thanks for the suggestion re: the clinical significance of this ADR. ―Biochemistry🙴❤ 05:20, 9 December 2017 (UTC)[reply]
Pharmacology
  • This whole section is more easy to read than I'd have expected given the subject matter - well done
Update
  •  Question: One more issue: "Conditions that involve excess gastric acid production (e.g. Zollinger-Ellison syndrome), conditions that are worsened by gastric acid (e.g. ulcerations of the gastrointestinal tract), and conditions whose pathophysiology are driven by gastric acid (e.g. symptomatic gastroesophageal reflux disease) are responsive to rabeprazole treatment" Sorry for addition at the last minute. Something not quite right here. Is Z-E syndrome really "Responsive to rabeprazole treatment"? is GERD's pathophysiology really "driven" by gastric acid? I think it might be most correct to remove the last bit and maybe reword "driven" somehow. --Tom (LT) (talk) 11:30, 7 December 2017 (UTC)[reply]
    • Rabeprazole is FDA-approved for the treatment of Z-E, so I'd argue that it is responsive to it. Given that rabeprazole is also FDA-approved for the treatment of GERD, and rabeprazole's primary MoA as an acid-suppressant, I'd also feel comfortable noting that GERD is driven by acid (though there are, of course, other factors that contribute to GERD and cause it, such as increases in abdominal pressure secondary to obesity, allowing the acid to insult the LES). I've reworded this bit under Medical uses to better reflect the role of gastric acid in GERD. Let me know what you think.―Biochemistry🙴❤ 05:36, 9 December 2017 (UTC)[reply]
      • Thank you, as you state GERD is more to do with the problem of reflux of gastric acid. I also fail to see how suppressing acid in ZE helps the underlying tumour [2]. If possible I would be most happy if we could compromise and reword this to something like "Rabeprazole is used in the management of..." and then remove the "are responsive to rabeprazole treatment". --Tom (LT) (talk) 21:25, 9 December 2017 (UTC)[reply]
        • I apologize for the delay; I didn't realize there was anything left besides the refs. I accept your proposed compromise. I've edited the lead section per your suggestion. ―Biochemistry🙴❤ 20:55, 13 December 2017 (UTC)[reply]

Thanks for your prompt replies too :). So, only three issues remaining - need some more information on that source, and the cancer bit inserted. --Tom (LT) (talk) 11:30, 7 December 2017 (UTC)[reply]

My pleasure! Let me know if there's anything I've missed! (: ―Biochemistry🙴❤ 05:37, 9 December 2017 (UTC)[reply]
No further issues identified. Have boldly made one small edit, and have promoted to GA - well done! --Tom (LT) (talk) 22:55, 14 December 2017 (UTC)[reply]
Thank you for your diligent review! (: ―Biochemistry🙴❤ 03:56, 18 December 2017 (UTC)[reply]
Retrieved from "https://mdwiki.org/wiki/Talk:Rabeprazole/GA1"